Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells

Sheng Cao,Lan Ma,Yulin Liu,Mingming Wei,Yuhong Yao,Chen Li,Ruonan Wang,Ning Liu,Zhiqiang Dong,Xuechun Li,Ming Li,Xiaoji Wang,Cheng Yang,Guang Yang
DOI: https://doi.org/10.1021/acs.jmedchem.1c00996
IF: 8.039
2021-10-25
Journal of Medicinal Chemistry
Abstract:Acute myeloid leukemia (AML) refers to one of the most lethal blood malignancies worldwide. FLT3-ITD mutation is recognized as the most common one that predicted a poorer prognosis. There have been many prominent FLT3-ITD inhibitors approved by the FDA for clinical therapies. However, as impacted by undesirable off-target effects, differentiated metabolic issues, and clinical drug resistance problems, it remains challenging to discover alternative and promising solutions for treating FLT3-ITD<sup>+</sup> AML. In this study, dovitinib was chemically modified and converted into CRBN-recruiting PROTACs. Two active compounds were identified, which showed enhanced antiproliferative effects against FLT3-ITD<sup>+</sup> AML cells, both <i>in vitro</i> and <i>in vivo</i>. As demonstrated from further biological evaluation, the compounds could induce the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely block their downstream signaling pathway. The findings of this study would provide another promising strategy to develop novel therapies for FLT3-ITD<sup>+</sup> AML.
chemistry, medicinal
What problem does this paper attempt to address?